Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Company Overview - Monopar Therapeutics Inc. (NASDAQ: MNPR) focuses on developing radiopharmaceutical solutions aimed at addressing unmet medical needs for cancer patients and rare diseases [1] - The company integrates radiodiagnostics and radiotherapeutics to visualize and eliminate cancer cells [1] Product Pipeline - MNPR has developed MNPR-101-Zr as an imaging agent, along with MNPR-101-Lu and MNPR-101-Ac, which are radiation-based therapies [1]